Psychiatrist explains: Auvelity, Caplyta, and Cobenfy

Añadido: 2026-06-01

[00:00:00]issues that I personally have as a practicing psychiatrist in examining the data and the new medications that exist is really the frankly the lack of comparative data. You'll have these pharmaceutical companies that will market and that will create all of these medications to market and there's still no no efficacy data comparing what currently exists on the market and so just kind of personally speaking, you know, that's not a particularly persuasive argument for a psychiatrist who already uses the existing medications to just say like, hey, you know, we have this medication. It's safe because we have the safety data on it.

[00:00:39]We've had the efficacy data comparing it to a placebo. You should just go ahead and try it. To me, that's not strong enough to be able to just kind of blindly prescribe a new medication that comes out. And don't get me wrong. I want there to be continued medication research because there's a lot of side effects to a lot of the medications that I prescribe to my patients and I wish there were better medications that existed out there. It's just that the new ones that have come out, there's just not enough data right now for me to just uniformly just prescribe people these new medications. You know, newer isn't necessarily better. I've used them. I've had some patients that have really good results being prescribed these medications. I've also had some patients who really didn't have very good experiences with these new medications. So, you know, as as always with any medication that comes out or any medication just in general, the individual responses are very varied and it requires a very nuanced conversation with your medical professional.